#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paraganglion neoplasm Chondrodystrophy Bronchopulmonary dysplasia Polycystic liver disease Autoimmune haemolytic anaemia Cutaneous T-cell lymphoma stage I Central nervous system lymphoma Bladder cancer Alveolar proteinosis T-cell lymphoma Non-small cell lung cancer Pseudoxanthoma elasticum Leukocyte adhesion deficiency type I Uveitis Orthostatic hypotension More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis II – Trials in Disease SAPHO syndrome – Treatment Combined immunodeficiency – Treatment Mucopolysaccharidosis I – Diagnostics Myxofibrosarcoma Haemophilia – Treatment Choroid melanoma – Basic Information Hereditary ataxia Kearns-Sayre syndrome – Life with Disease Antithrombin III deficiency – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    FERUMOXTRAN-10 Norucholic Acid Eplerenone Azelastine Medi0618 Brimonidine Tartrate Formoterol Fumarate Dihydrate Molidustat Sodium Ambrisentan Cefixime Trihydrate Omaveloxolone Englumafusp Alfa Radiprodil Bi 1015550 Rozanolixizumab Chlorhexidine Dihydrochloride Amitriptyline Hydrochloride TRAZODONE HYDROCHLORIDE Tolinapant Lactate Allogeneic Faecal Microbiota More therapies…

    Learn about Your Condition

    Haemoglobinuria Candida infection Diabetic autonomic neuropathy Peritoneal sarcoma Dementia Alzheimer's type Bladder cancer stage II Varicella Apathy Urethral valves Plasma cell myeloma Neurofibrosarcoma Hypomagnesaemia Hand fracture Chronic sinusitis Low cardiac output syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Metastatic malignant melanoma

  • Study on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
    France

  • Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Incb099280
    • Ipilimumab
    Norway Slovakia Sweden

  • Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Austria Belgium Denmark Finland France Germany +7

  • Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Io102 Hydrochloride
    • Pembrolizumab
    Belgium Czechia Denmark France Germany Hungary +4

  • Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Desmoplastic melanoma
    • Malignant melanoma of eyelid
    • Malignant melanoma stage IV
    Investigated Drugs:
    • Atl001
    • Nivolumab
    Spain

  • Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Melanoma recurrent
    • Malignant melanoma stage III
    Investigated Drugs:
    • Autogene Cevumeran
    • Pembrolizumab
    Germany Spain
Previous Page
1 2 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!